Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Long-term weight maintenance is the ultimate test of any obesity treatment. The STEP 5 trial by Garvey, Batterham, Bhatta, and colleagues, published in Nature Medicine, specifically examined semaglutide's effects over a two-year treatment period in adults with overweight or obesity.

The trial followed participants receiving weekly semaglutide for two years, measuring body weight changes, metabolic parameters, and safety outcomes throughout this extended period. This long-duration design addressed the critical question of whether semaglutide's weight loss benefits persist with continued treatment.

The results demonstrated that semaglutide maintains significant weight loss over the full two-year study period, providing compelling evidence for the long-term durability of its obesity treatment effects. This sustained efficacy distinguishes semaglutide from many previous weight loss interventions that showed diminishing returns over time.

The establishment of two-year weight loss durability is a milestone for obesity pharmacotherapy. For patients, this means confidence that semaglutide can deliver lasting results, fundamentally changing the trajectory of their weight management journey and supporting sustained improvements in metabolic health.